NHS NEL
Demonstration Formulary
 
back
6 Endocrine system

 

 

 

06-01-02-03 SGL2 inhibitors

Canagliflozin
Formulary

For treating Type 2 diabetes  in line with NICE, and chronic kidney disease.

Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis) 

Link  MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
Link  MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
Link  MHRA: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
Link  MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Green View adult BNF  View SPC online  View childrens BNF
Dapagliflozin
Formulary

 

  for treating Type 2 diabetes and chronic kidney disease in line with NICE 

Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)

Amber Recommended Treatment of all grades of symptomatic heart failure 

 

SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)

Link  MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
Link  NICE TA775: Dapagliflozin for treating chronic kidney disease
Link  NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Link  MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes

View adult BNF  View SPC online  View childrens BNF
Empagliflozin
Formulary

 Green For treating type 2 diabetes
Do not use SGLT2-inhibitors in patients with T1DM, regardless of CKD and/or heart failure status due to risk of DKA (diabetic ketoacidosis)

Amber Recommended treatment of all grades of symptomatic heart failure

SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis

MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)

Link  MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
Link  MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
Link  MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
Link  NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
Link  NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

View adult BNF  View SPC online  View childrens BNF
Empagliflozin/Linagliptin
Formulary

 

 

 


Green View adult BNF  View SPC online  View childrens BNF
Ertugliflozin
Formulary

In line with NICE


Do not use SGLT2-inhibitors in patients with T1DM,
regardless of CKD and/or heart failure status due to risk
of DKA (diabetic ketoacidosis)

 

Link  MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
Link  NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Link  MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
Link  NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes

Green View adult BNF  View SPC online  View childrens BNF